STRATA Skin Sciences Announced That the Ministry of Health, Labor and Welfare Approved the XTRAC Momentum™ 1.0 Device in Japan, Specifically Designed to Treat Inflammatory Skin Conditions On July 2...
CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will...
Find More
Inspira™ Secured Approval From Israeli Authorities for its INSPIRA™ ART100 System On July 11, 2024, Inspira™ Technologies OXY B.H.N. Ltd., a pioneering medical technology company, secured a pivotal milestone with the receipt of the Israeli Ministry of Health's medical devices and accessories ("AMAR") approval fo...
Find More
Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Immutep Limited announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, evaluating eftilagimod alfa (efti) combined with MSD’s anti-PD-1 therapy KEYTR...
Find More
Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites On July 9, 2024, Cordis, a leading company in cardiovascular and endovascular technology, received FDA approval for its MYNX CONTROL™ VENOUS Vascular Closure Device. Thi...
Find More
Lilly Strengthens IBD Treatment Portfolio with Morphic Acquisition Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for serious chronic diseases. Lilly will initiate a tender offer to acqu...
Find More
Artivion Amended Agreements With Endospan On June 01, 2024, Artivion, Inc. a prominent company in cardiac and vascular surgery specializing in aortic disease, announced that it revised its credit facility and option purchase agreements with Endospan Ltd. ("Endospan"), an Israeli-based, privately-held developer o...
Find More
Eisai Announces Solo Venture for Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate Eisai Co., Ltd. announced the termination of its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), previously known as MORAb-202, an ...
Find More
Alcon's Newest Technological Marvels, Unity VCS, and Unity CS, Achieved 510(k) Clearance From the U.S. FDA, Paving the Way for New Advancements On June 24, 2024, Alcon, the foremost name in eye care with a mission to help people see brilliantly, revealed that the U.S. Food and Drug Administration (FDA) had...
Find More
Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...
Find More
Lyme disease is a vector-borne infectious disease that spreads primarily by the bite of a tick (also.....
Find More
Well, MDS being one of the rare blood cancers, has been into the limelight of researchers since a de.....
Find More
Asthma is a chronic disease of the air passages characterized by inflammation and narrowing of the a.....
Find More
The most common lysosomal disease, Gaucher Disease is a result of lack of sufficient glucocerebrosid.....
Find More
A formal medical disorder affecting approximately 10 percent of the world population is trypanophobi.....
Find More
Anorexia Nervosa (AN) is a psychological condition that is characterized by an abnormally low weight.....
Find More-Agonist.png "Toll-like Receptors Agonist")
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!
